Long-term follow-up after triple treatment of prostate cancer stage pT3

References

• Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007; 41: 456–77
   PubMed Web of Science ®Google Scholar
• Bill-Axelsson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group 4 randomized trial. J Natl Cancer Inst 2008; 100: 1144–54
   PubMedGoogle Scholar
• Hernandez, DJ, Nielsen, ME, Han, M, Trock, BJ, Partin, AW, Walsh, PC, , et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 2008;February 25, epub.
   Google Scholar
• Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095–101
   PubMed Web of Science ®Google Scholar
• Solberg A, Viset T, Haugen OA, Mjönes J, Klepp O, Angelsen A. Histopathological outcome in 167 patients operated on with radical retropubic prostatectomy. Scand J Urol Nephrol 2005; 39: 283–8
   PubMed Web of Science ®Google Scholar
• Steuber T, Erbesdobler A, Graefen M, Haese A, Huland H, Karakiewicz PI. Comparative assessment of the 1992 and 2002 pathologic T3 substages for prediction of biochemical recurrence after radical prostatectomy. Cancer 2006; 106: 775–82
   PubMed Web of Science ®Google Scholar
• Berge V, Thompson T, Blackman D. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation or watchful waiting. Scand J Urol Nephrol 2007; 41: 198–203
   PubMed Web of Science ®Google Scholar
• Hugosson J, Abrahamsson PA, Ahlgren G, Aus G, Lundberg S, Schain M, et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced about three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 1996; 29: 413–9
   PubMed Web of Science ®Google Scholar
• Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomised controlled trial. BJU Int 2002; 90: 561–6
   PubMed Web of Science ®Google Scholar
• Anscher MS, Robertsson CN, Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/T4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys 1995; 33: 37–43
   PubMed Web of Science ®Google Scholar
• Schröder F, Hermanek P, Denis L, Fair WR, Gospoddarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992; Suppl 4: 129–38
   Google Scholar
• Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273–9
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Collete L, van Cangh P, Vekemans C, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572–8
   PubMed Web of Science ®Google Scholar
• Petrovich Z, Lieskovsky G, Langholz B, Josef G, Streeter OE, Skinner DG. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 600–9
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer – a randomized clinical trial. JAMA 2006; 296: 2329–35
   PubMed Web of Science ®Google Scholar
• Kumar, S, Shelley, M, Harrison, C, Coles, B, Wilt, T, Mason, MD. Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;4: CD006019.
   Google Scholar
• Bolla M, Colette L, Blank L, Warde P, Dubois JB, Mirimanoff RM, et al. Long-term results with immediate androgen suppression and external beam irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–6
   PubMed Web of Science ®Google Scholar
• Roach M III, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short term neoadjuvant deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26: 585–91
   PubMed Web of Science ®Google Scholar
• Widmark, A, Klepp, O, Solberg, A, Damber, JE, Angelsson, A, Fransson, P, , et al. Endocrine treatment, with or without radiotherapy in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 2008; December 15, epub.
   PubMed Web of Science ®Google Scholar
• Corn BW, Winter K, Pilepich MV. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Urology 1999; 54: 495–502
   PubMed Web of Science ®Google Scholar
• Katz MS, Zelefsky MJ, Ennapadam S, Venkatraman S, Fuks Z, Hummer A, et al. Prediction of biochemical outcome with salvage coinformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003; 21: 483–9
   PubMed Web of Science ®Google Scholar
• Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M III, Wolkov HB, et al. Effect of a short course of neoadjuvant hormonal therapy on the response of subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomised protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002; 54: 1302–10
   PubMed Web of Science ®Google Scholar